GLP-1受体激动剂使用与膝骨关节炎全膝关节置换风险:回顾性数据库分析
本研究基于TriNetX全球研究网络开展回顾性队列研究,纳入2010至2024年诊断为膝骨关节炎的成人,按GLP-1受体激动剂暴露类别和疗程分层并与倾向评分匹配的非暴露队列比较。结果显示GLP-1受体激动剂使用与全膝关节置换累积发生率显著降低相关,新一代药物和更长疗程者风险降幅更大。
要点
- GLP-1受体激动剂使用与膝骨关节炎患者全膝关节置换长期风险显著降低相关。
- 新一代药物(司美格鲁肽或替尔泊肽)及3年暴露的风险降幅大于1年暴露。
- 上述关联提示可能超越单纯减重的疾病修饰作用,但需前瞻性试验证实因果。
核心结论
- 在这项大型多中心真实世界队列研究中,GLP-1受体激动剂使用与膝骨关节炎患者长期全膝关节置换风险显著降低相关。
- 风险降低幅度随治疗时间延长和使用新一代药物而增大。
- 疗程和药物依赖性关联提示可能存在超越减重本身的潜在疾病修饰活性,但需前瞻性试验确立因果并确定最佳治疗目标。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球研究网络数据。
- 按GLP-1受体激动剂暴露类别(任何GLP-1受体激动剂或新一代药物司美格鲁肽/替尔泊肽)和治疗时长(1年或3年)分层。
- 与倾向评分匹配的非暴露队列比较,匹配变量包括年龄、性别、种族、肌肉骨骼诊断、肥胖相关疾病、体重指数和医疗可及性代理指标。
主要发现
- GLP-1受体激动剂使用在所有暴露类别、疗程和随访时间点上均与全膝关节置换累积发生率显著降低相关(所有p<0.001)。
- 任何GLP-1受体激动剂1年暴露,8年绝对风险差为-2.80个百分点(HR 0.90,95%CI 0.83至0.98)。
- 司美格鲁肽或替尔泊肽3年暴露,8年绝对风险差为-4.71个百分点(HR 0.72,95%CI 0.67至0.78)。
关键数值与推荐
- 主要结局为1年、3年、5年和8年全膝关节置换累积发生率。
- 风险比通过Cox比例风险模型估计,绝对风险差通过Kaplan-Meier曲线计算,表示为暴露组减非暴露组。
- 任何GLP-1受体激动剂1年暴露8年绝对风险差-2.80个百分点(HR 0.90,95%CI 0.83至0.98)。
- 司美格鲁肽或替尔泊肽3年暴露8年绝对风险差-4.71个百分点(HR 0.72,95%CI 0.67至0.78)。
临床怎么用
- 对于合并膝骨关节炎的GLP-1受体激动剂适用患者,该药可能同时降低全膝关节置换长期风险。
- 新一代药物和更长疗程与更大风险降幅相关,临床决策时可纳入考量。
- 上述关联来自回顾性研究,不能直接确立因果,需结合前瞻性试验结果审慎应用。
局限性
- 为回顾性数据库分析,存在残余混杂可能。
- 需前瞻性试验确立因果并确定最佳治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Knee osteoarthritis (OA) is a leading cause of chronic pain and disability, with limited disease modifying therapies. While glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have established cardiometabolic benefits and have been associated with reductions in knee OA related pain, it is unclear whether they can reduce progression to total knee arthroplasty (TKA). METHODS: We conducted a retrospective cohort study using the TriNetX Global Research Network, identifying adults with knee OA diagnosed between January 1, 2010, and December 31, 2024. Patients were stratified by GLP-1 RA exposure class (any GLP-1 RA or new generation agents, semaglutide or tirzepatide) and treatment duration (1 or 3 years), and then compared with propensity score matched non-exposed cohorts balanced for age, sex, race, musculoskeletal diagnoses, obesity related conditions, body mass index, and proxies for healthcare access. The primary outcome was cumulative incidence of TKA at 1, 3, 5, and 8 years. Hazard ratios (HRs) were estimated by Cox proportional hazards models and absolute risk differences from Kaplan-Meier curves, expressed as exposed minus non-exposed. RESULTS: After propensity score matching, cohort sizes ranged from 13 351 (new generation GLP-1 RA, 3 year exposure) to 42 062 patients (any GLP-1 RA, 1 year exposure). GLP-1 RA use was associated with significantly lower cumulative TKA incidence across all exposure classes, durations, and follow-up intervals (all p<0.001). With 1 year exposure to any GLP-1 RA, the absolute risk difference at 8 years was -2.80 percentage points (HR 0.90, 95% CI 0.83 to 0.98). Risk reductions were greater with new generation agents and longer duration: 3 year exposure to semaglutide or tirzepatide gave an absolute risk difference of -4.71 percentage points at 8 years (HR 0.72, 95% CI 0.67 to 0.78). CONCLUSIONS: In this large, multicenter, real world cohort study, GLP-1 RA use was associated with a significantly reduced long term risk of TKA in patients with knee OA, with effects that were greater with longer treatment duration and newer generation agents. These duration and agent dependent associations are consistent with potential disease modifying activity beyond weight loss alone, although prospective trials are needed to establish causality and define optimal treatment targets.
引用
- Carter V, Desverreaux E, Amin I, et al. Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. Reg Anesth Pain Med. 2026. PMID: 42229941. doi:10.1136/rapm-2026-107658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。